Table 3 Bivariate analysis of socio-demographic and clinical characteristics that affect time to immunological recovery among 427 patients initiated on ART at JCRC, during 2002–2006
Variables | Unadjusted hazard ratio | 95% CI | p-value |
|---|---|---|---|
Sex | |||
Male | 1.00 | ||
Female | 1.02 | 0.81–1.28 | 0.879 |
Age (years) | |||
≤ 40 | 1.00 | ||
> 40 | 1.25 | 1.01–1.56 | 0.046 |
Group status | |||
ADC | 1.00 | ||
Non-ADC | 1.33 | 1.05–1.69 | 0.020 |
CD4 (cells/μl) | |||
>200 | 1.00 | ||
≤ 200 | 0.77 | 0.60–0.98 | 0.034 |
Viral load (log 10 copies/ml) | |||
< 6.0 | 1.00 | ||
≥ 6.0 | 0.93 | 0.88–0.98 | 0.007 |
Hemoglobin (g/dl) | |||
≤ 10.0 | 1.00 | ||
> 10.0 | 0.87 | 0.64–1.19 | 0.387 |
Prophylaxis | 1.00 | ||
Cotrimoxazole | 0.97 | 0.51–1.83 | 0.926 |
Dapsone | 0.82 | 0.58–1.16 | 0.274 |
Fluconazole | 0.97 | 0.72–1.30 | 0.830 |
None | |||
Adherence level (%) | |||
<95 | 1.00 | ||
≥ 95 | 2.31 | 1.84–2.90 | 0.001 |
Weight (kg) | |||
≤ 60.0 | 1.00 | ||
> 60.0 | 0.81 | 0.64–1.01 | 0.067 |
ART regimen | |||
Non-protease inhibitor-based | 1.00 | ||
Protease inhibitor-based | 0.86 | 0.59–1.26 | 0.446 |
Total lymphocyte count (cells/mm 3 ) × 10 3 | |||
< 1.2 | 1.00 | ||
≥ 1.2 | 1.55 | 1.04–2.30 | 0.031 |